Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206

RCT (n=221) reports, at median follow-up of 24.1 month, irinotecan plus cisplatin was not superior to etoposide plus cisplatin for improving relapse free survival (69.0% vs. 65.4%, respectively, hazard ratio 1.076, 95% CI, 0.666 to 1.738 p=0.619).

Journal of Clinical Oncology